The $10 billion de-extinction firm, led by Ben Lamm, has acquired Austin’s Viagen Pets and Equine to advance its species preservation mission.

Colossal Biosciences, the world’s de-extinction company, today announced its acquisition of Viagen Pets and Equine, the ...

Viagen Pets and Equine is a biotechnology company that will produce genetic twins of customers' pets and livestock. But its conservation efforts are what attracted Colossal.

Colossal’s purchase of ViaGen, known for cloning pets of celebrities, bolsters the biotech firm’s tools for de-extinction and ...

Colossal Biosciences, which has brought to life a small pack of genetically modified dire wolves, has acquired cloning ...

Colossal, the company behind efforts to de-extinct the woolly mammoth and other long gone species announced Tuesday its ...

Thus far, cinema has been a powerful medium used to demystify complex topics ranging from feminist discourse (Barbie) to ...

GS&C, a biotech company, based in Sausalito, California, also made significant advances in canine cloning research before going out of business in 2006. Clearly, the cost of a faithful reproduction ...

The U.S. market is anticipated to rise from USD 0.43 billion in 2024 to USD 0.95 billion by 2032, reflecting a strong 10.52% CAGR, supported by advanced biopharmaceutical infrastructure, regulatory ...

Discover how ant queens of Messor ibericus produce drones of two species, revealing unique reproductive strategies and cloning phenomena.

Instead, we risk repeating an old mistake: mistaking regulatory efficiency for good governance. In a time when consumer trust ...

Cloning in agriculture means producing an exact genetic copy of an animal, usually for breeding purposes. The clones ...